$3 B

IOVA Mkt cap, 31-Dec-2021
Iovance Biotherapeutics Net income (Q1, 2021)-75.4 M
Iovance Biotherapeutics EBIT (Q1, 2021)-75.6 M
Iovance Biotherapeutics Cash, 31-Mar-2021132 M
Iovance Biotherapeutics EV3 B
Get notified regarding key financial metrics and revenue changes at Iovance BiotherapeuticsLearn more
Banner background

Iovance Biotherapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

R&D expense

1.8m1.7m1.3m2.7m15.5m28.0m71.6m99.8m166.0m201.7m

General and administrative expense

12.4m25.6m21.3m28.4m40.8m60.2m

Operating expense total

1.8m1.7m1.3m2.7m27.9m53.6m92.9m128.3m206.9m261.9m

EBIT

(21.2m)(8.1m)(22.6m)(12.0m)(27.9m)(53.6m)(92.9m)(128.3m)(206.9m)(261.9m)

Interest expense

151.5k1.9m444.7k200.0k

Interest income

745.0k813.0k4.7m9.3m2.4m

Income tax expense

Net Income

(25.7m)(3.3m)(25.4m)(12.0m)(27.7m)(52.9m)(92.1m)(123.6m)(197.6m)(259.6m)

Iovance Biotherapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

510.2k19.7m44.9m13.6m106.7m145.4m82.2m14.0m67.3m

Prepaid Expenses

4.5k5.0k15.0k66.1k277.0k3.9m6.9m9.4m6.7m

Inventories

3.0m

Current Assets

524.1k7.3k19.8m45.0m104.0m169.5m149.3m475.4m316.5m636.1m

PP&E

28.3k22.1k27.8k1.5m1.7m2.4m2.5m2.7m8.5m59.2m

Total Assets

568.4k29.4k19.9m46.5m105.7m171.9m155.4m480.8m344.7m768.5m

Accounts Payable

190.0k1.1m413.0k1.2m958.0k863.0k1.2m2.7m15.6m13.5m

Short-term debt

6.3m

Current Liabilities

13.3m11.3m2.3m1.7m1.6m5.0m9.9m14.4m39.1m54.9m

Long-term debt

4.2m45.4m

Non-Current Liabilities

230.0k6.6m57.1m

Total Debt

4.2m51.7m

Total Liabilities

14.6m45.7m112.0m

Common Stock

3.3k3.4k835.01.4k2.0k3.0k5.0k5.0k6.0k

Preferred Stock

17.06.0

Additional Paid-in Capital

14.6m19.1m81.9m121.2m208.0m324.0m394.7m839.0m869.4m1.5b

Retained Earnings

(27.4m)(30.7m)(64.5m)(76.6m)(104.2m)(157.1m)(249.2m)(372.8m)(570.6m)(830.2m)

Total Equity

(12.8m)(11.3m)17.6m44.8m104.0m166.9m145.5m466.2m299.0m656.5m

Financial Leverage

0 x0 x1.1 x1 x1 x1 x1.1 x1 x1.2 x1.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

268.6k910.6k15.7k569.6k129.8k17.9m18.4m17.2m111.3m12.6m10.2m8.9m101.2m92.9m107.1m114.3m163.4m297.1m246.0m80.7m54.1m76.9m38.9m52.5m160.6m68.3m132.0m

Prepaid Expenses

34.1k8.6k5.0k5.0k5.0k5.0k10.0k9.7k15.1k128.9k378.4k245.0k193.0k782.0k1.3m5.4m6.4m8.0m5.6m3.7m5.9m4.7m6.8m5.4m10.7m10.8m9.4m11.3m

Current Assets

326.1k3.3m34.1k24.4k5.0k8.2k578.7k138.7k18.1m18.5m17.2m111.4m112.7m110.4m99.4m192.4m180.6m152.6m135.4m171.4m302.7m279.8m265.9m444.8m410.9m367.3m256.4m782.7m723.6m605.2m

PP&E

16.3k18.8k26.8k25.2k23.7k20.2k19.0k29.9k14.6k15.8k171.0k2.1m2.0m1.8m1.4m1.2m1.8m2.8m2.6m2.6m2.2m2.7m2.6m3.5m4.5m5.9m13.6m18.7m39.1m72.8m

Total Assets

466.2k3.4m76.8k65.6k28.7k28.3k597.7k168.6k18.1m18.5m17.4m113.5m114.7m112.2m100.8m193.5m182.3m155.4m138.0m174.0m307.2m284.8m270.8m461.5m435.9m395.7m288.3m817.6m782.3m750.6m

Accounts Payable

130.6k206.9k504.3k609.3k841.6k1.3m1.5m1.6m286.3k440.6k573.8k1.1m1.2m1.2m1.1m725.0k228.0k2.2m3.7m2.9m6.6m5.2m6.0m7.6m12.8m9.9m10.6m10.2m24.8m13.4m

Short-term debt

6.4m5.9m7.2m5.9m

Current Liabilities

1.9m9.1m17.3m16.7m16.6m12.3m3.4m3.5m1.1m1.2m1.3m1.9m1.9m2.9m1.8m4.6m3.2m5.5m8.9m8.5m14.7m14.2m16.7m22.1m33.8m34.6m39.5m54.9m64.4m55.1m

Long-term debt

4.4m4.6m6.0m3.1m2.0m3.7m48.1m

Non-Current Liabilities

4.4m4.7m6.1m5.4m4.4m6.1m48.1m

Total Debt

4.4m4.6m6.0m9.5m7.9m10.9m54.0m

Total Liabilities

26.6m38.5m40.7m45.0m59.3m70.5m103.1m

Common Stock

3.2k3.3k3.3k3.3k3.3k34.0556.0629.0921.01.1k1.2k1.9k2.0k2.0k2.0k3.0k3.0k3.0k3.0k3.0k3.0k4.0k4.0k5.0k5.0k5.0k5.0k6.0k6.0k6.0k

Preferred Stock

13.06.06.04.04.0

Additional Paid-in Capital

11.8m13.3m15.9m16.4m17.1m19.2m31.7m40.6m83.3m86.0m87.6m193.2m200.8m204.9m209.7m311.3m320.1m327.7m330.3m388.8m568.2m576.9m594.5m844.8m372.0k239.0k882.6m1.5b1.5b1.6b

Retained Earnings

(13.2m)(19.0m)(33.1m)(33.5m)(34.2m)(31.7m)(35.2m)(44.6m)(66.8m)(68.9m)(71.7m)(81.9m)(88.2m)(95.8m)(111.1m)(122.7m)(141.4m)(177.8m)(201.2m)(223.3m)(275.7m)(306.4m)(340.2m)(410.0m)(457.6m)(507.0m)(640.2m)(703.2m)(761.8m)(905.6m)

Total Equity

(1.4m)(5.7m)(17.3m)(16.6m)(16.6m)(12.3m)(2.8m)(3.3m)16.8m17.4m16.2m111.6m112.9m109.4m98.9m188.9m179.1m149.9m129.2m165.4m292.6m270.6m254.2m434.9m397.4m355.1m243.3m758.3m711.8m647.4m

Financial Leverage

-0.3 x-0.6 x0 x0 x0 x0 x-0.2 x-0.1 x1.1 x1.1 x1.1 x1 x1 x1 x1 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.1 x1.1 x1.2 x

Iovance Biotherapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(11.5m)(17.3m)(5.8m)(6.1m)(6.8m)(1.0m)(4.5m)(13.9m)(2.3m)(4.4m)(7.2m)(5.3m)(11.7m)(19.3m)(6.9m)(18.4m)(37.2m)(20.7m)(44.1m)(66.2m)(26.5m)(57.2m)(91.0m)(36.9m)(84.5m)(134.0m)(132.6m)

Depreciation and Amortization

36.8k55.9k1.6k3.1k4.7k2.0k3.1k4.9k16.6k17.7k22.8k185.4k425.6k691.0k269.0k540.0k688.0k221.0k464.0k710.0k228.0k453.0k704.0k271.0k560.0k875.0k252.0k512.0k819.0k372.0k

Accounts Payable

100.3k208.2k372.2k700.1k1.4m658.1k976.3k670.6k(1.2m)(1.1m)(1.0m)249.0k204.4k1.2m200.0k3.0m1.3m1.5m3.0m2.1m5.2m3.7m4.8m4.6m10.0m6.6m(7.8m)(7.1m)9.2m(15.0k)

Cash From Operating Activities

(1.8m)(3.5m)(760.2k)(2.0m)(2.2m)(300.0k)(981.9k)(1.4m)(2.3m)(3.6m)(5.3m)3.5m(8.0m)(11.8m)(4.6m)(8.3m)(20.5m)(18.8m)(36.3m)(57.7m)(17.8m)(41.8m)(69.7m)(29.1m)(62.9m)(105.1m)(65.3m)(101.9m)(142.4m)(62.4m)

Purchases of PP&E

16.9k20.3k(12.7k)(3.4k)(5.7k)(166.0k)(782.1k)(919.1k)(992.0k)(2.0k)(56.0k)(781.0k)(798.0k)(823.0k)(1.1m)(22.0k)(440.0k)(903.0k)(824.0k)(2.3m)(3.5m)(637.0k)(5.6m)(23.5m)(10.7m)

Cash From Investing Activities

(16.9k)(20.3k)(12.7k)(3.4k)(5.7k)(166.0k)(100.7m)(100.9m)(147.0k)(314.0k)(16.9m)18.8m44.1m58.6m(22.0k)(30.5m)(179.9m)1.0m59.7m63.2m100.1m(323.7m)(376.6m)77.2m

Cash From Financing Activities

823.0k3.1m250.0k1.5m1.7m300.0k1.6m1.6m542.5k2.4m3.0m70.6m76.3m78.0m96.2m96.7m383.0k(265.0k)55.8m169.6m172.9m185.0m(2.0k)3.4m4.0m3.8m572.3m573.5m50.4m

Net Change in Cash

(1.0m)(381.9k)(510.2k)(494.5k)(510.2k)569.6k129.8k(1.7m)(1.2m)(2.5m)66.4m(32.4m)(34.7m)(4.7m)87.6m59.3m382.0k7.6m56.7m151.7m100.6m(64.6m)(28.1m)210.0k(37.8m)38.6m146.7m54.4m65.2m

Interest Paid

Income Taxes Paid

Iovance Biotherapeutics Ratios

USDQ2, 2011

Financial Leverage

-0.3 x

Iovance Biotherapeutics Employee Rating

2.928 votes
Culture & Values
1.7
Work/Life Balance
1.8
Senior Management
1.9
Salary & Benefits
2.5
Career Opportunities
2.2
Source